<DOC>
	<DOC>NCT00556608</DOC>
	<brief_summary>The purpose of this study is to prove the non-inferiority of the intra-articular injection of hyaluronic acid (Sinovial®) in the symptomatic treatment of knee OA in comparison to Synvisc®.</brief_summary>
	<brief_title>Efficacy Study of Intra-articular Hyaluronic Acid in the Knee Osteoarthritis</brief_title>
	<detailed_description />
	<mesh_term>Osteoarthritis</mesh_term>
	<mesh_term>Osteoarthritis, Knee</mesh_term>
	<mesh_term>Pharmaceutical Solutions</mesh_term>
	<mesh_term>Hyaluronic Acid</mesh_term>
	<mesh_term>Hylan</mesh_term>
	<criteria>Age between 40 and 80 years Primary knee OA of the medial or lateral femorotibial compartment Symptoms for at least 3 months Diagnosis according to ACR criteria Kellgren &amp; Lawrence radiological grade 23 Patients who failed to respond sufficiently (not responders) to analgesics and/or NSAIDs taken regularly or responders intolerant to the regular use of analgesics and/or NSAIDs. Mean WOMAC pain subscore at the target knee &gt;= 40 mm and &lt; 80 mm on a VAS at baseline after washout from analgesics/NSAIDs· If bilateral knee OA: definition of the most symptomatic joint at screening based on patient's evaluation and Investigator's clinical judgment and mean WOMAC pain subscore at baseline in the contralateral knee &lt; 30 mm Written informed consent Subject able to understand, cooperative and reliable BMI &gt;= 32 kg/m2 Secondary (posttraumatic) knee OA Predominantly patellofemoral pain/syndrome No remaining joint space width Symptomatic hip OA or other interfering health condition Severe varus/valgus deformity (&gt;15°) History/present evidence of (target knee): inflammatory, infective or metabolic joint diseases; recurrent clinical chondrocalcinosis; crystal arthropaties; osteoarticular pathologies differing from arthrosis; articular fracture; ochronosis; acromegaly; haemochromatosis; Wilson's disease; primary osteochondromatosis; heritable disorders; collagen gene mutations. Concomitant rheumatic disease Significant injury to the target knee in the last 6 months Previous joint replacement/arthroplasty (target knee) Arthroscopy/osteotomy/surgery in the past 1 year (target knee) Any surgery scheduled in the next 6 months Venous or lymphatic stasis in the relevant limb Skin infection/disease/trauma at the injection site Systemic or i.a. (target knee) corticosteroids in the past 3 months I.a. corticosteroids (nontarget joint) in the past 4 weeks Viscosupplementation (target knee) in the past year Recently started (in the last 3 months) physical therapy (target knee) Recently (in the last 3 months) started therapy or change in dosage of SYSADOAs Ongoing anticoagulant therapy Chronic or recurrent use of NSAIDs/analgesics/narcotics because of diseases different from OA of the target knee History of allergy or hypersensitivity to hyaluronic acid or paracetamol or avian proteins Participation in a clinical study in the last 3 months Pregnant or lactating women, and women of childbearing potential not willing to use adequate contraception Patients unable to stay in the study for 6 months, noncooperating, not able to understand</criteria>
	<gender>All</gender>
	<minimum_age>40 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>November 2012</verification_date>
</DOC>